![Ola Melin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Positionen von Ola Melin
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CIRCIO HOLDING ASA | Geschäftsführer | - | - |
Corporate Officer/Principal | 01.10.2021 | - |
Karriereverlauf von Ola Melin
Ehemalige bekannte Positionen von Ola Melin
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
OxThera AB
![]() OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | - | - |
Ausbildung von Ola Melin
Mälardalen University | Undergraduate Degree |
Statistik
International
Schweden | 4 |
Norwegen | 2 |
Operativ
Corporate Officer/Principal | 2 |
Chief Operating Officer | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
CIRCIO HOLDING ASA | Health Technology |
Private Unternehmen | 1 |
---|---|
OxThera AB
![]() OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |